IL17A and myeloid sarcoma: Thus, this study aimed to analyze the cytokine profile in MS patients treated with glatiramer acetate, interferon β 1a, and fingolimod, with the different clinical forms of the disease, as well as to identify a possible contribution of T CD4+ IFN-γ+ IL-17+ cells in MS pathophysiology.